A Phase II Study of the Dual Immune Checkpoint Blockade with Durvalumab (MEDI4736) plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy
Primary Objective: To determine the efficacy of the dual immune checkpoint blockade with durvalumab plus tremelimumab following a small dose of hypofractionated palliative radiation in patients with MSS mCRC who have progressed on chemotherapy
Patient Population: patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) who have progressed on chemotherapy
Target Accrual: 21 patients
Status: closed to accrual
ClinicalTrials.gov Identifier: NCT03007407
The Mission of NSABP Foundation, Inc. is to design and conduct practice changing cancer research, including clinical trials and laboratory studies in the medical, surgical and prevention settings in order to improve the survival outcome and quality of life of patients with breast and colorectal cancer, and to disseminate the results of NSABP collaborative research to benefit the world-wide community.
NSABP Foundation Inc.
Nova Tower 2
Two Allegheny Center – Suite 1200
Pittsburgh, PA 15212-5402